IMPEDIMED LIMITED (IPD)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

IPD

IPD - IMPEDIMED LIMITED

FNArena Sector : Medical Equipment & Devices
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: -0.93
Index:

0

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.004

09 Nov
2026

0.001

OPEN

$0.00

33.33%

HIGH

$0.00

247,788

LOW

$0.00

TARGET
$0.01 137.5% upside
OTHER COMPANIES IN THE SAME SECTOR
4DX . AT1 . AVE . AYA . BB1 . BRN . CAT . CBL . CGS . CMP . COH . CSX . CTE . CU6 . CVB . CYC . EBR . EIQ . EMV . EYE . FPH . IME . IMR . LDX . MX1 . NAN . ONE . PCK . PEB . PGC . PME . RAP . RMD . SHG . SLD . SOM . TRJ .
FNARENA'S MARKET CONSENSUS FORECASTS
IPD: 1
Title FY25
Actual		 FY26
Actual		 FY27
Forecast		 FY28
Forecast
EPS (cps) xxx - 1.2 - 0.2 xxx
DPS (cps) xxx 0.0 0.0 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A N/A xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2026 FactSet UK Limited. All rights reserved
Title 202120222023202420252026
EPS Basic xxxxxxxxxxxxxxx-1.2
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx14.6 M
Book Value Per Share xxxxxxxxxxxxxxx0.3
Net Operating Cash Flow xxxxxxxxxxxxxxx-20.0 M
Net Profit Margin xxxxxxxxxxxxxxx-170.44 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202120222023202420252026
Return on Capital Employed xxxxxxxxxxxxxxx-162.35 %
Return on Invested Capital xxxxxxxxxxxxxxx-81.38 %
Return on Assets xxxxxxxxxxxxxxx-65.27 %
Return on Equity xxxxxxxxxxxxxxx-162.35 %
Return on Total Capital xxxxxxxxxxxxxxx-71.57 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-20.1 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202120222023202420252026
Short-Term Debt xxxxxxxxxxxxxxx0 M
Long Term Debt xxxxxxxxxxxxxxx16 M
Total Debt xxxxxxxxxxxxxxx17 M
Goodwill - Gross xxxxxxxxxxxxxxx3 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx15 M
Price To Book Value xxxxxxxxxxxxxxx1.80

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202120222023202420252026
Capex xxxxxxxxxxxxxxx1.3 M
Capex % of Sales xxxxxxxxxxxxxxx8.70 %
Cost of Goods Sold xxxxxxxxxxxxxxx27 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx10 M
Research & Development xxxxxxxxxxxxxxx0 M
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.5

No. Of Recommendations

3
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Ord Minnett

xx/xx/xxxx

0

xxxxxxxxx xx xxxxxxxx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Bell Potter

02/11/2026

1

Speculative Buy

$0.01

150.00%

Bell Potter was disappointed with the first quarter sales outcome from ImpediMed. Most of the sales were in BCRL, with none in heart health and just a few in Body Composition.

The company has advised that necessary changes to the commercial team may disrupt the timing of cash flow breakeven, although it is seeking to mitigate the disruption.

The broker maintains its expectations for EBITDA breakeven in FY29 and retains a Speculative Buy rating. Target is reduced to 1.0c from 1.5c.

FORECAST
Bell Potter forecasts a full year FY27 dividend of 0.00 cents and EPS of minus -0.40 cents.
Bell Potter forecasts a full year FY28 dividend of 0.00 cents and EPS of minus -0.20 cents.

Morgans

xx/xx/xxxx

3

xxxxxxxxx xx xxxx xxxx xxxxxxxxxxx xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

0

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY
Access Extra Coverage Research History >

IPD STOCK CHART

FNArena News on IPD

1
Weekly Ratings, Targets, Forecast Changes – 04-09-26

Sep 07 2026 - Weekly Reports
2
FNArena Corporate Results Monitor – 28-08-2026

Aug 28 2026 - Australia
3
FNArena Corporate Results Monitor – 27-02-2026

Feb 27 2026 - Australia
4
Australian Broker Call *Extra* Edition – Feb 05, 2026

Feb 05 2026 - Daily Market Reports
5
ImpediMed Ready To Scale Up

Dec 16 2025 - Small Caps

Latest Medical Equipment & Devices News

1
Strong ResMed Result Comes With Caveats

Nov 03 2026 - Australia
2
Vitrafy Eyes US Blood Breakthrough

Oct 06 2026 - Small Caps
3
Undervalued Catapult Sports Plays A Bigger Game

Sep 16 2026 - Small Caps
4
Rudi Interviewed: Bear Market Be Gone

Aug 13 2026 - Rudi's View
5
Are Headwinds Building For ResMed In FY27?

Jul 14 2026 - Australia
6
A Technical Breakout For ResMed

Jul 07 2026 - Technicals
7
Awaiting Catapult Sports’ Fundamental Re-Rating

Jun 15 2026 - Small Caps
8
Treasure Chest: Pro Medicus

Jun 04 2026 - Treasure Chest
9
Cochlear’s Shock Downgrade Raises Concerns

Apr 23 2026 - Australia
10
GLP-1s Drive Strong Quarter For ResMed

Feb 02 2026 - Australia